BioTime Enters into Worldwide License Agreement with UCLA to Develop Therapy for the Treatment of Stroke
ALAMEDA, Calif.--(Healthcare Sales & Marketing Network)--BioTime, Inc. (NYSE MKT: BTX) today announced that it has entered into an exclusive license agreement with the University of California, Los Angeles (UCLA) for novel technology related to the treatme... Regenerative Medicine, Neurology, LicensingBioTime, HyStem hydrogel, stroke, stem cell
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Brain | Marketing | Neurology | Pharmaceuticals | Stem Cell Therapy | Stem Cells | Stroke